IP Library Granted Patent US 8,404,725
Granted Patent B2
US 8,404,725 · App. 13/057,052 · Granted Mar 26, 2013

Phenylamino isonicotinamide compounds

Inventors: Andreas Goutopoulos (Boston, MA); Henry Yu (Bedford, MA); Benny C. Askew, Jr. (Marshfield, MA); Lesley Liu-Bujalski (Bedford, MA)
Assignee: Merck Patent GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,404,725
App. No.
13/057,052
Granted
Mar 26, 2013
Kind
B2
Abstract

The invention provides novel substituted phenylamino isonicotinamide compounds (I), pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein X, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the specification. Said compounds are MEK inhibitors useful in the treatment of hyperproliferative diseases related to the hyperactivity of MEK, such as restenosis, as well as diseases modulated by the MEK cascade, such as cancer and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Claims (54)

1. A compound of Formula (II)

and pharmaceutically acceptable salts, wherein:

R 1 is hydrogen, methyl, ethyl, n-propyl, i-propyl, SH or Hal,

R 2 is hydrogen, methoxy, ethoxy, acetylene, cyano, SH or Hal,

R 3 , R 4 are independently selected from hydrogen, SH or Hal, and

Hal is F, Cl, Br or I.

2. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

and pharmaceutically acceptable salts.

3. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt as active ingredient, together with a pharmaceutically acceptable carrier.

4. A pharmaceutical composition comprising a compound according to claim 2 , or a pharmaceutically acceptable salt as active ingredient, together with a pharmaceutically acceptable carrier.

5. A compound of claim 1 , according to one of the following Subformulae,

Subformula IA:

R 1 is Hal, methyl or ethyl,

R 2 is hydrogen, Hal, methoxy or acetylene,

R 3 is hydrogen or Hal,

R 4 is hydrogen or Hal,

Hal is F, Cl, Br or I,

in Subformula IB

R 1 is Hal,

R 2 is hydrogen or Hal,

R 3 is hydrogen or Hal,

R 4 is hydrogen or Hal,

Hal is F, Cl, Br or I,

in Subformula IC

R 1 is F, Cl, methyl or ethyl,

R 2 is hydrogen, I, Br, methoxy or acetylene,

R 3 is hydrogen or Hal,

R 4 is hydrogen or Hal,

Hal is F, Cl, Br or I,

in Subformula ID

R 1 is F, Cl, methyl or ethyl,

R 2 is hydrogen, I, Br, methoxy or acetylene,

R 3 is hydrogen or F,

R 4 is hydrogen or Cl

in Subformula IE

R 1 is F or Cl,

R 2 is I or Br,

R 3 is hydrogen or F,

R 4 is hydrogen or Cl

in Subformula IF

R 1 is F or Cl,

R 2 is I or Br,

R 3 is hydrogen or F,

R 4 is hydrogen or Cl,

in Subformula IG

R 1 is F or Cl,

R 2 is I or Br,

R 3 is hydrogen,

R 4 is hydrogen,

and in Subformula IH

R 1 is F,

R 2 is I,

R 3 is hydrogen or F,

R 4 is hydrogen or Cl.

Continuity (2)
Provisional Application 61137858 · Aug 4, 2008
Related Publication 20110184032A1 · Jul 28, 2011